GSK: Jemperli Plus Chemotherapy Receives Positive CHMP Opinion to Expand Approval to All Adult Patients With Primary Advanced or Recurrent Endometrial Cancer
December 17, 2024
December 17, 2024
LONDON, England, Dec. 17 (TNSres) -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company issued the following news release on Dec. 16, 2024:
* * *
- Positive opinion based on statistically significant and clinically meaningful progression-free and overall survival data from phase III RUBY trial
- An expanded approval would include MMRp/MSS tumours, which represent majority of endometrial cancer cases
- Approval decision expected in Q1 2 . . .
* * *
- Positive opinion based on statistically significant and clinically meaningful progression-free and overall survival data from phase III RUBY trial
- An expanded approval would include MMRp/MSS tumours, which represent majority of endometrial cancer cases
- Approval decision expected in Q1 2 . . .